Master Alliance Provisions Guide (MAPGuide)

BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments

  • Equitable Access | Access plans & principles

1. Subject to the other terms of this agreement, BMGF hereby releases CureVac of any and all Global Access Commitments (as defined in the BMGF Agreements on the Effective Date) for the following vaccines and other medicines developed or to be developed under the CLA:

a) Any vaccine based on CureVac’s mRNA technology platform for the prophylaxis or treatment of [*****] virus infections in humans (“[*****] Vaccines”), which may include, without limitation:

i) an [*****] vaccine based on CureVac’s mRNA technology platform that is expected to [*****] (“[*****] Vaccine”),

ii) an [*****] vaccine based on CureVac’s mRNA technology platform offering broad protection [*****] (“[*****]Vaccine”), and

iii) an influenza vaccine based on CureVac’s mRNA technology platform providing prophylaxis or treatment of a [*****] of [*****] virus infections in humans (“[*****] Vaccine”). (The [*****] Vaccines developed and/or commercialized under the CLA shall be referred to as the “GSK [*****] Vaccines.”)

b) Any vaccine or other medicine based on CureVac’s mRNA technology platform for the prophylaxis and/or treatment of a[*****] virus infection.

c) Any vaccine or other medicine based on CureVac’s mRNA technology platform for the prophylaxis and/or treatment of a human [*****] infection.

(the vaccines and medicines referred to in items (a) to (c) inclusive shall jointly be referred to as the “CLA Products“).